Mp259glycoprotein Sclerostin and Vascular Calcification in Patients With Chronic Kidney Disease

Борисов, А. А.; Milоvаnоvа, Ludmilа; Ermolaeva, I.Yu.; Kozlovskaya, Lidia; Мухин, Н А; Dudareva, Anna

doi:10.1093/ndt/gfw188.15

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, other studies showed that Scl level was positively associated with abdominal aortic calcification, 14 valve calcification 38,51 and coronary artery calcification. 39,52 The extent of Scl expression in vessels or serum was strongly correlated with the degree of medial calcification in biopsy samples, indicating that a high Scl level was predictive of VC occurrence. 39,53 A plausible explanation for this positive relationship is that, as a defensive response or compensatory mechanism, a high Scl level might counteract the progression of VC.…”

Section: Discussionmentioning

confidence: 99%

Meta-analysis of the association between sclerostin level and adverse clinical outcomes in patients undergoing maintenance haemodialysis

Zhang

et al. 2021

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Background: Studies regarding the relationship of sclerostin (Scl) with clinical outcomes in patients undergoing maintenance haemodialysis have yielded controversial findings. This meta-analysis was performed to investigate the predictive role of Scl in this patient population. Methods: Several electronic medical databases (e.g. PubMed, Embase, Web of Science and Cochrane Library) were searched for eligible studies through December 20, 2019. Summary hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated based on Scr level (high or low) using a random or fixed effects model. Results: From among 641 initially screened publications, 16 eligible studies were included in this meta-analysis. A high Scl level was not associated with cardiovascular events [HR = 0.8 (95% CI, 0.42–1.35)] or all-cause mortality [HR = 0.93 (95% CI, 0.56–1.54)]. There was high heterogeneity, but no evidence of publication bias. Interestingly, a high Scl level was associated with reduced cardiovascular events [HR = 0.44 (95% CI, 0.29–0.69)] in the subgroup by shorter follow-up period or all-cause mortality [pooled HR = 0.58 (95% CI, 0.36–0.91)] by shorter dialysis vintage. Conclusion: This meta-analysis indicated that a high Scl level did not predict total clinical outcomes in patients undergoing maintenance haemodialysis despite survival benefits in the subgroups. The predictive role of Scl in these patients should be further evaluated in large prospective studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Meta-analysis of the association between sclerostin level and adverse clinical outcomes in patients undergoing maintenance haemodialysis

Zhang

et al. 2021

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

Mp259glycoprotein Sclerostin and Vascular Calcification in Patients With Chronic Kidney Disease

Cited by 1 publication

References 0 publications

Meta-analysis of the association between sclerostin level and adverse clinical outcomes in patients undergoing maintenance haemodialysis

Meta-analysis of the association between sclerostin level and adverse clinical outcomes in patients undergoing maintenance haemodialysis

Contact Info

Product

Resources

About